Brain, Vol 121, Issue 7 1343-1355, Copyright © 1998 by Oxford University Press
AD Lawrence, RA Weeks, DJ Brooks, TC Andrews, LH Watkins, AE Harding, TW Robbins and BJ Sahakian
Seventeen individuals at risk for Huntington's disease and five symptomatic
patients, who had previously undergone [11C]SCH23390 and [11C]raclopride
PET to assess in vivo levels of striatal dopamine D1 and D2 receptor
binding, had neuropsychological assessment on a series of tests known to be
sensitive to symptomatic Huntington's disease, including tests of verbal
fluency, memory, attention and planning. Compared with age- and IQ-matched
healthy volunteers, clinically symptomatic carriers of the Huntington's
disease mutation were found to be impaired on tests of verbal fluency,
spatial span, planning and sequence generation, as were clinically
asymptomatic Huntington's disease mutation carriers. In asymptomatic
individuals, both striatal dopamine receptor levels and cognitive
performance were lower in subjects approaching their estimated age of
onset. In addition, performance on these tasks was found to correlate with
PET measures of striatal D1 and D2 receptor binding levels, especially D2
binding. These results are consistent with a role for the striatum, as part
of the complex corticobasal ganglia-thalamocortical circuitry, in the
optimal scheduling and sequencing of responses, and suggest that cognitive
manifestations of striatal dysfunction can be evidenced in carriers of the
Huntington's disease mutation prior to the onset of overt clinical movement
disorder.
ARTICLES
The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease
Department of Experimental Psychology, University of Cambridge, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Brandt, A. B. Inscore, J. Ward, B. Shpritz, A. Rosenblatt, R. L. Margolis, and C. A. Ross Neuropsychological Deficits in Huntington's Disease Gene Carriers and Correlates of Early "Conversion" J Neuropsychiatry Clin Neurosci, November 1, 2008; 20(4): 466 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. De Diego-Balaguer, M. Couette, G. Dolbeau, A. Durr, K. Youssov, and A.-C. Bachoud-Levi Striatal degeneration impairs language learning: evidence from Huntington's disease Brain, November 1, 2008; 131(11): 2870 - 2881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Wolf, N. Vasic, C. Schonfeldt-Lecuona, G. B. Landwehrmeyer, and D. Ecker Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI Brain, November 1, 2007; 130(11): 2845 - 2857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gomez-Anson, M. Alegret, E. Munoz, A. Sainz, G. C. Monte, and E. Tolosa Decreased frontal choline and neuropsychological performance in preclinical Huntington disease Neurology, March 20, 2007; 68(12): 906 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Van Raamsdonk, J. Pearson, E. J. Slow, S. M. Hossain, B. R. Leavitt, and M. R. Hayden Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease J. Neurosci., April 20, 2005; 25(16): 4169 - 4180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Aylward, B. F. Sparks, K. M. Field, V. Yallapragada, B. D. Shpritz, A. Rosenblatt, J. Brandt, L. M. Gourley, K. Liang, H. Zhou, et al. Onset and rate of striatal atrophy in preclinical Huntington disease Neurology, July 13, 2004; 63(1): 66 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peschanski, A.-C. Bachoud-Levi, and P. Hantraye Integrating fetal neural transplants into a therapeutic strategy: the example of Huntington's disease Brain, June 1, 2004; 127(6): 1219 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pavese, T. C. Andrews, D. J. Brooks, A. K. Ho, A. E. Rosser, R. A. Barker, T. W. Robbins, B. J. Sahakian, S. B. Dunnett, and P. Piccini Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study Brain, May 1, 2003; 126(5): 1127 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Modregger, N. A. DiProspero, V. Charles, D. A. Tagle, and M. Plomann PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains Hum. Mol. Genet., October 2, 2002; 11(21): 2547 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Thieben, A. J. Duggins, C. D. Good, L. Gomes, N. Mahant, F. Richards, E. McCusker, and R. S. J. Frackowiak The distribution of structural neuropathology in pre-clinical Huntington's disease Brain, August 1, 2002; 125(8): 1815 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Thompson, J. S. Snowden, D. Craufurd, and D. Neary Behavior in Huntington's Disease: Dissociating Cognition-Based and Mood-Based Changes J Neuropsychiatry Clin Neurosci, February 1, 2002; 14(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Brown, L. Redondo-Verge, J. R. Chacon, M. L. Lucas, and S. Channon Dissociation between intentional and incidental sequence learning in Huntington's disease Brain, November 1, 2001; 124(11): 2188 - 2202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Paulsen, H. Zhao, J. C. Stout, R. R. Brinkman, M. Guttman, C. A. Ross, P. Como, C. Manning, M. R. Hayden, and I. Shoulson Clinical markers of early disease in persons near onset of Huntington's disease Neurology, August 28, 2001; 57(4): 658 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sanchez-Pernaute, G. Kunig, A. del Barrio Alba, J. G. de Yebenes, P. Vontobel, and K. L. Leenders Bradykinesia in early Huntington's disease Neurology, January 11, 2000; 54(1): 119 - 119. [Abstract] [Full Text] [PDF]
|
|